RxDoctor Payments Data

Sean Foley

Physician Assistant · Milford, MANPI 1225769565

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 116 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,476 and has fallen 93.8% since, to $91 in 2025. Among physician assistant clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,626in general payments, 2019–2025

Across 116 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$615
  • AbbVie$524
  • Takeda Pharmaceuticals U.S.A., Inc.$234
  • Gilead$176
  • Phathom Pharmaceuticals, Inc.$168
  • Sanofi$143
  • plus $766 from 15 others

What the payments were for

  • Food & beverage$2,60199%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,626 in reported general payments places this provider in the 90th percentile of 3,507 physician assistant providers in Massachusetts.

See all physician assistant providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$11,780
Medicare patients
73
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide22$17,034
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C68$9,667
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag21$2,539
Omeprazole44$844
Pantoprazole Sodium22$312
Famotidine13$266
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl13$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$524$17,03422 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$615$9,66768 claims
Braintree Laboratories, Inc.Suflave$22$2,53921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,507 physician assistant providers in Massachusetts.

Other physician assistant in Milford

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →